PriceTargets.com logo

Insulet - PODD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $253.27
  • Forecasted Upside: -4.99%
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$266.58 As of 11/20/2024 01:00 AM ET
▲ +4.59 (1.75%)

This chart shows the closing price for PODD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Insulet Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PODD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PODD

Analyst Price Target is $253.27
▼ -4.99% Downside Potential
This price target is based on 15 analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is $253.27, with a high forecast of $317.00 and a low forecast of $200.00. The average price target represents a -4.99% upside from the last price of $266.58.

This chart shows the closing price for PODD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 15 investment analysts is to moderate buy stock in Insulet. This rating has held steady since July 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$220.00 ➝ $234.00
11/11/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$234.00 ➝ $317.00
11/8/2024BTIG ResearchBoost TargetBuy ➝ Buy$260.00 ➝ $270.00
11/6/2024Sanford C. BernsteinInitiated CoverageOutperform$300.00
10/14/2024BTIG ResearchBoost TargetBuy ➝ Buy$250.00 ➝ $260.00
10/14/2024Raymond JamesBoost TargetOutperform ➝ Outperform$213.00 ➝ $260.00
10/1/2024CitigroupBoost TargetBuy ➝ Buy$250.00 ➝ $275.00
9/25/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$236.00 ➝ $269.00
9/17/2024Piper SandlerBoost TargetOverweight ➝ Overweight$230.00 ➝ $285.00
8/12/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$200.00 ➝ $220.00
8/9/2024BTIG ResearchLower TargetBuy ➝ Buy$270.00 ➝ $250.00
8/9/2024UBS GroupBoost TargetNeutral ➝ Neutral$211.00 ➝ $223.00
7/23/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$234.00 ➝ $234.00
6/10/2024OTR GlobalReiterated RatingPositive ➝ Mixed
5/30/2024Redburn AtlanticInitiated CoverageBuy$235.00
5/13/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$213.00 ➝ $200.00
5/10/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$226.00 ➝ $234.00
5/10/2024Raymond JamesLower TargetOutperform ➝ Outperform$218.00 ➝ $213.00
5/10/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$255.00 ➝ $260.00
5/7/2024Wolfe ResearchUpgradePeer Perform ➝ Outperform$200.00
2/26/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$214.00 ➝ $213.00
2/23/2024Piper SandlerLower TargetOverweight ➝ Overweight$250.00 ➝ $230.00
2/23/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$190.00 ➝ $225.00
2/5/2024Stifel NicolausBoost TargetHold ➝ Hold$163.00 ➝ $208.00
12/21/2023Robert W. BairdUpgradeNeutral ➝ Outperform$180.00 ➝ $238.00
12/4/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$185.00 ➝ $234.00
11/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$325.00 ➝ $250.00
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$325.00 ➝ $162.00
10/16/2023Leerink PartnrsReiterated RatingOutperform
10/16/2023Leerink PartnersInitiated CoverageOutperform$184.00
10/2/2023Jefferies Financial GroupUpgradeHold ➝ Buy$260.00 ➝ $240.00
9/29/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$208.00 ➝ $185.00
9/15/2023Raymond JamesLower TargetOutperform ➝ Outperform$299.00 ➝ $228.00
9/6/2023UBS GroupLower TargetNeutral ➝ Neutral$270.00 ➝ $215.00
8/24/2023Bank of AmericaLower TargetBuy ➝ Buy$365.00 ➝ $295.00
8/24/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$343.00 ➝ $208.00
8/21/2023Robert W. BairdDowngradeOutperform ➝ Neutral$320.00 ➝ $219.00
8/21/2023CitigroupUpgradeNeutral ➝ Buy$273.00 ➝ $265.00
8/10/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$329.00 ➝ $257.00
8/9/2023Raymond JamesLower TargetOutperform ➝ Outperform$350.00 ➝ $299.00
8/9/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$365.00 ➝ $325.00
8/9/2023TD CowenLower TargetOutperform ➝ Outperform$350.00 ➝ $300.00
8/9/2023Piper SandlerLower Target$360.00 ➝ $325.00
8/9/2023Robert W. BairdLower Target$370.00 ➝ $320.00
8/9/2023CitigroupLower TargetNeutral ➝ Neutral$319.00 ➝ $273.00
8/9/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$375.00 ➝ $330.00
7/10/2023CitigroupLower Target$330.00 ➝ $319.00
5/8/2023BarclaysBoost Target$292.00 ➝ $329.00
5/5/2023UBS GroupBoost Target$328.00 ➝ $360.00
5/5/2023Piper SandlerBoost Target$340.00 ➝ $360.00
5/5/2023Robert W. BairdBoost Target$350.00 ➝ $370.00
4/20/2023Stifel NicolausBoost TargetHold$300.00 ➝ $342.00
4/17/2023BTIG ResearchBoost TargetBuy$340.00 ➝ $350.00
3/28/2023UBS GroupInitiated CoverageNeutral
2/24/2023Morgan StanleyBoost TargetEqual Weight$320.00 ➝ $325.00
2/24/2023Raymond JamesBoost TargetOutperform$320.00 ➝ $334.00
2/24/2023Robert W. BairdBoost TargetOutperform$340.00 ➝ $350.00
2/24/2023BarclaysBoost Target$245.00 ➝ $292.00
1/26/2023Wolfe ResearchInitiated CoveragePeer Perform
1/6/2023Morgan StanleyBoost TargetEqual Weight$300.00 ➝ $320.00
1/4/2023BarclaysBoost Target$238.00 ➝ $245.00
12/12/2022Robert W. BairdBoost Target$315.00 ➝ $340.00
12/12/2022CitigroupBoost Target$270.00 ➝ $330.00
11/4/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$290.00 ➝ $310.00
11/4/2022BTIG ResearchBoost Target$285.00 ➝ $320.00
11/4/2022CitigroupBoost Target$260.00 ➝ $270.00
11/4/2022Morgan StanleyBoost TargetEqual Weight$273.00 ➝ $300.00
11/4/2022Piper SandlerUpgradeNeutral ➝ Overweight$235.00 ➝ $340.00
11/4/2022Robert W. BairdBoost TargetOutperform$300.00 ➝ $315.00
11/4/2022Raymond JamesBoost TargetOutperform$280.00 ➝ $320.00
10/17/2022BarclaysInitiated CoverageEqual Weight$238.00
10/12/2022Jefferies Financial GroupInitiated CoverageHold$260.00
8/9/2022CitigroupBoost Target$260.00
8/9/2022BTIG ResearchBoost Target$285.00
8/8/2022Morgan StanleyBoost TargetEqual Weight$244.00 ➝ $273.00
8/8/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$250.00 ➝ $290.00
8/5/2022Canaccord Genuity GroupBoost TargetBuy$250.00 ➝ $290.00
8/5/2022Robert W. BairdBoost TargetOutperform$245.00 ➝ $300.00
8/5/2022Raymond JamesBoost Target$262.00 ➝ $280.00
8/5/2022Piper SandlerBoost TargetNeutral$230.00 ➝ $235.00
7/11/2022CitigroupDowngradeBuy ➝ Neutral$310.00 ➝ $250.00
6/24/2022BTIG ResearchLower TargetBuy$310.00 ➝ $250.00
6/7/2022Morgan StanleyLower TargetEqual Weight$268.00 ➝ $244.00
5/17/2022CitigroupLower TargetBuy$350.00 ➝ $310.00
5/6/2022Wells Fargo & CompanyLower Target$357.00 ➝ $345.00
3/2/2022Bank of AmericaInitiated CoverageBuy ➝ Buy
2/25/2022Morgan StanleyLower TargetEqual Weight$300.00 ➝ $268.00
2/24/2022Raymond JamesLower TargetOutperform$329.00 ➝ $280.00
2/24/2022Robert W. BairdLower Target$315.00 ➝ $275.00
2/24/2022Piper SandlerLower TargetNeutral$295.00 ➝ $230.00
2/3/2022BTIG ResearchUpgradeNeutral ➝ Buy$320.00
2/2/2022UBS GroupUpgradeNeutral ➝ Buy$325.00
1/31/2022OppenheimerUpgradeMarket Perform ➝ Outperform$300.00 ➝ $275.00
1/7/2022Morgan StanleyLower TargetEqual Weight$303.00 ➝ $300.00
12/7/2021Leerink PartnersReiterated RatingBuy
11/8/2021Raymond JamesBoost TargetOutperform$285.00 ➝ $329.00
11/5/2021Morgan StanleyBoost TargetEqual Weight$276.00 ➝ $303.00
11/5/2021Leerink PartnersBoost TargetOutperform$300.00 ➝ $350.00
11/5/2021CitigroupBoost TargetBuy$325.00 ➝ $350.00
11/5/2021Piper SandlerBoost TargetNeutral$262.00 ➝ $295.00
8/6/2021Leerink PartnersLower TargetOutperform$325.00 ➝ $300.00
8/6/2021CitigroupBoost TargetBuy$310.00 ➝ $325.00
7/21/2021CowenBoost TargetOutperform$285.00 ➝ $310.00
7/20/2021Leerink PartnersBoost TargetOutperform$300.00 ➝ $325.00
5/24/2021BarclaysInitiated CoverageOverweight$300.00
5/7/2021Raymond JamesLower TargetOutperform$296.00 ➝ $285.00
5/7/2021Leerink PartnersLower TargetOutperform$320.00 ➝ $300.00
5/7/2021Piper SandlerLower TargetNeutral$260.00 ➝ $250.00
5/7/2021BTIG ResearchReiterated RatingHold
4/1/2021Leerink PartnersUpgradeMarket Perform ➝ Outperform$275.00 ➝ $320.00
3/2/2021Leerink PartnersBoost TargetMarket Perform$255.00 ➝ $275.00
2/25/2021OppenheimerBoost TargetMarket Perform$235.00 ➝ $277.00
2/24/2021Leerink PartnersReiterated RatingMarket Perform$255.00 ➝ $275.00
2/24/2021Raymond JamesBoost TargetOutperform$282.00 ➝ $296.00
2/1/2021BTIG ResearchReiterated RatingHold
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$260.00
1/15/2021Wells Fargo & CompanyReiterated RatingBuy
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$255.00 ➝ $268.00
12/15/2020Morgan StanleyBoost TargetEqual Weight$246.00 ➝ $276.00
11/5/2020UBS GroupBoost TargetNeutral$230.00 ➝ $245.00
11/5/2020Wells Fargo & CompanyBoost TargetOverweight$250.00 ➝ $266.00
11/5/2020Raymond JamesBoost TargetOutperform$249.00 ➝ $250.00
11/5/2020Morgan StanleyBoost TargetEqual Weight$232.00 ➝ $246.00
10/12/2020Leerink PartnersBoost TargetMarket Perform$240.00 ➝ $255.00
8/7/2020Morgan StanleyBoost TargetEqual Weight$222.00 ➝ $232.00
8/7/2020OppenheimerReiterated RatingHold$235.00
8/7/2020StephensBoost TargetPositive ➝ Equal Weight$165.00 ➝ $230.00
8/7/2020Leerink PartnersBoost TargetMarket Perform$215.00 ➝ $240.00
8/7/2020Raymond JamesBoost TargetOutperform$200.00 ➝ $249.00
8/7/2020CitigroupBoost TargetBuy$200.00 ➝ $255.00
8/6/2020Piper SandlerReiterated RatingOverweight$235.00 ➝ $260.00
7/28/2020Wells Fargo & CompanyInitiated CoverageOverweight$231.00
7/7/2020CowenBoost TargetPositive ➝ Outperform$220.00 ➝ $230.00
6/9/2020Raymond JamesLower TargetOutperform$220.00 ➝ $200.00
5/8/2020CfraBoost TargetSell$162.00 ➝ $179.00
5/8/2020UBS GroupBoost TargetNeutral$195.00 ➝ $213.00
5/8/2020Stifel NicolausBoost TargetHold$161.00 ➝ $195.00
5/8/2020JPMorgan Chase & Co.Boost TargetOverweight$200.00 ➝ $235.00
5/8/2020Robert W. BairdBoost Target$189.00 ➝ $242.00
5/8/2020Morgan StanleyBoost TargetEqual Weight$186.00 ➝ $222.00
5/8/2020Leerink PartnersBoost TargetMarket Perform$200.00 ➝ $230.00
5/8/2020CitigroupBoost TargetBuy$206.00 ➝ $250.00
4/27/2020Raymond JamesBoost TargetOutperform$205.00 ➝ $220.00
4/24/2020Leerink PartnersDowngradeOutperform ➝ Market Perform
4/3/2020Bank of AmericaInitiated CoverageNeutral$200.00
3/31/2020Berenberg BankDowngradeBuy ➝ Hold
3/27/2020Morgan StanleyBoost TargetEqual Weight$181.00 ➝ $186.00
3/27/2020CitigroupLower TargetBuy$220.00 ➝ $206.00
3/4/2020CitigroupInitiated CoverageBuy$220.00
2/26/2020Piper SandlerReiterated RatingBuy$200.00
2/26/2020CowenReiterated RatingBuy
2/26/2020CfraLower TargetSell$163.00 ➝ $162.00
2/26/2020Robert W. BairdLower TargetOutperform$225.00 ➝ $215.00
2/26/2020BTIG ResearchReiterated RatingHold
2/26/2020Raymond JamesLower TargetOutperform$213.00 ➝ $205.00
2/6/2020Raymond JamesBoost TargetOutperform$158.00 ➝ $213.00
12/20/2019JPMorgan Chase & Co.Boost TargetOverweight$170.00 ➝ $200.00
12/17/2019Morgan StanleyBoost TargetEqual Weight$148.00 ➝ $181.00
12/10/2019CfraInitiated CoverageSell$163.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.96 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 26 very positive mentions
  • 19 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 29 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 16 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 25 very positive mentions
  • 30 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 27 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 24 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 33 very positive mentions
  • 27 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 33 very positive mentions
  • 27 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Insulet logo
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Read More

Today's Range

Now: $266.58
Low: $260.63
High: $267.05

50 Day Range

MA: $240.09
Low: $227.79
High: $275.70

52 Week Range

Now: $266.58
Low: $160.19
High: $279.40

Volume

504,270 shs

Average Volume

777,377 shs

Market Capitalization

$18.70 billion

P/E Ratio

45.65

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Insulet?

The following Wall Street sell-side analysts have issued reports on Insulet in the last year: Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, OTR Global, Piper Sandler, Raymond James, Redburn Atlantic, Robert W. Baird, Sanford C. Bernstein, Stifel Nicolaus, UBS Group AG, and Wolfe Research.
View the latest analyst ratings for PODD.

What is the current price target for Insulet?

0 Wall Street analysts have set twelve-month price targets for Insulet in the last year. Their average twelve-month price target is $253.27, suggesting a possible downside of 5.0%. Morgan Stanley has the highest price target set, predicting PODD will reach $317.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $200.00 for Insulet in the next year.
View the latest price targets for PODD.

What is the current consensus analyst rating for Insulet?

Insulet currently has 3 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PODD.

What other companies compete with Insulet?

Other companies that are similar to Insulet include Abiomed, iRhythm Technologies, NovoCure, Becton, Dickinson and Company and Edwards Lifesciences. Learn More about companies similar to Insulet.

How do I contact Insulet's investor relations team?

Insulet's physical mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier's listed phone number is (978) 600-7000 and its investor relations email address is [email protected]. The official website for Insulet is www.insulet.com. Learn More about contacing Insulet investor relations.